Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device company developing and commercializing innovative, interventional treatment systems for vascular disease, will present at two upcoming health care conferences: the Citi 2011 Global Health Care Conference at the Hilton New York Hotel, and the RBC Capital Markets Health Care Conference at the Palace Hotel, both in New York. President and Chief Executive Officer David L. Martin will provide an overview of the company and its growth opportunities at the Citi conference and will participate in the Innovations in Cardiovascular Devices panel at the RBC conference.


Citi 2011 Global Health Care Conference
Tuesday, March 1; 11 a.m. EST
Hilton New York Hotel
New York

RBC Capital Markets Health Care Conference
Wednesday, March 2; 1:35 p.m. EST
Palace Hotel
New York


To listen to a live webcast of either presentation, go to the investor information section of the company’s website,, and click on the respective webcast icon. The RBC webcast will be audio only. Both webcasts will be archived for 30 days after the conclusion of Cardiovascular Systems’ live presentations.
If you have any difficulty accessing the webcast, please contact

Mick Forgey: (612) 455-1789;

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing interventional treatment systems for vascular disease. The company’s Diamondback 360 ® and Diamondback Predator 360°™ PAD Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. As many as 12 million Americans suffer from peripheral arterial disease (PAD), which is caused by the accumulation of plaque in peripheral arteries (commonly the pelvis or leg) reducing blood flow. Symptoms include leg pain when walking or at rest, and can lead to tissue loss and eventually limb amputation. In August 2007, the U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° as a therapy for PAD, and CSI commenced a U.S. product launch in September 2007. Since then, more than 37,000 procedures have been performed using the Diamondback 360° in leading institutions across the United States. For more information visit the company’s Web site at

Copyright Business Wire 2010